Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.

[1]  D. Rubens,et al.  Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. , 2017, Thrombosis research.

[2]  A. Rutjes,et al.  Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2016, The Cochrane database of systematic reviews.

[3]  K. Hood,et al.  Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Dörken,et al.  Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Khorana,et al.  Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[6]  Gary H Lyman,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Liebman,et al.  Approach to the management of incidental venous thromboembolic events in patients with cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  C. Riquelme,et al.  Incidental venous thromboembolism detected by PET-CT in patients with cancer: prevalence and impact on survival rate. , 2014, Thrombosis research.

[9]  R. Rosell,et al.  Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. , 2013, Thrombosis research.

[10]  P. Liaw,et al.  Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. , 2012, Thrombosis research.

[11]  A. Maraveyas,et al.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. , 2012, European journal of cancer.

[12]  A. Khorana.  Cancer and coagulation , 2012, American journal of hematology.

[13]  S. Solymoss,et al.  A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer , 2012, Journal of thrombosis and haemostasis : JTH.

[14]  A. Turpie,et al.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. , 2012, The New England journal of medicine.

[15]  D. Heigener,et al.  Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[16]  Judy L. Smith,et al.  Venous thromboembolic disease. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  Derick R. Peterson,et al.  Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer , 2011, Thrombosis and Haemostasis.

[18]  O. Dekkers,et al.  Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Prins,et al.  Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Razavi,et al.  Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning , 2011, Journal of thrombosis and haemostasis : JTH.

[21]  C. Marosi,et al.  Prediction of venous thromboembolism in cancer patients. , 2010, Blood.

[22]  M. Malkin,et al.  PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma , 2010, Journal of thrombosis and haemostasis : JTH.

[23]  R. Coleman,et al.  Treatment and secondary prevention of venous thromboembolism in cancer , 2010, British Journal of Cancer.

[24]  A. Stanley,et al.  Primary prevention of venous thromboembolism in medical and surgical oncology patients , 2010, British Journal of Cancer.

[25]  S. Noble,et al.  Epidemiology and pathophysiology of cancer-associated thrombosis , 2010, British Journal of Cancer.

[26]  A. Cohen,et al.  VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients. , 2010, Thrombosis research.

[27]  T. Nokes,et al.  Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics , 2009, Thrombosis and Haemostasis.

[28]  A. Khorana,et al.  Assessing risk of venous thromboembolism in the patient with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Barni,et al.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. , 2009, The Lancet. Oncology.

[30]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[31]  A. Khorana,et al.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients , 2008, Cancer.

[32]  F. Rosendaal,et al.  Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study , 2006, Journal of thrombosis and haemostasis : JTH.

[33]  A. Unal,et al.  A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.

[34]  M. Prins,et al.  Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. , 2004, Archives of internal medicine.

[35]  J. Olsen,et al.  Prognosis of cancers associated with venous thromboembolism. , 2000, The New England journal of medicine.

[36]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.